THERAKOS™ Photopheresis (foh-toh-fuh-REE-siss) is a therapy designed to reduce the skin symptoms associated with CTCL.
The therapy involves the intravenous (IV) collection of blood from your body and the treatment of that blood, first with a medication, then with UVA light, after which the blood is returned to your body.
THERAKOS™ Photopheresis is also known as extracorporeal photopheresis (ECP), photoimmune therapy, and immune cell therapy.
In multiple clinical trials, THERAKOS™ Photopheresis has been shown to reduce the signs and symptoms of CTCL.4,5
In many patients, THERAKOS™ Photopheresis has very positive effects, although not all patients will respond. Some people may experience decreased itching and redness, whereas others may have noticeable or complete clearing of the skin. As with any medical treatment, it is difficult to predict the type and extent of response you will have.
Only you and your doctor can determine whether THERAKOS™ Photopheresis is right for you.
THERAKOS™ Photopheresis has an established safety record, having been used for over 20 years in more than 500,000 treatments.4 Its safety has been demonstrated in a long-term clinical trial (more than 5 years’ follow-up).6 And THERAKOS™ Photopheresis does not increase your risk for infection or additional cancers.8,11 Risks associated with the procedure include a drop in blood pressure, fever, or worsening of skin redness, which usually resolves in 1 day.
There are 2 types of instruments that deliver THERAKOS™ Photopheresis: THERAKOS™ CELLEX® and THERAKOS™ UVAR XTS® Photopheresis Systems. Both instruments work similarly to provide ECP.
Ask your doctor if THERAKOS™ Photopheresis therapy may be right for you.
The side effects of THERAKOS™ Photopheresis are listed below:
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen is not appropriate for patients who have had a reaction to psoralen compounds, patients who have had a light sensitive disease, or patients with an absence of one or both lenses of the eye.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate blood volume changes or patients with blood clotting disorders. See Important Safety Information for additional details.